17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
14:30 , Sep 13, 2018 |  BC Extra  |  Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
17:49 , Apr 6, 2018 |  BC Week In Review  |  Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting...
16:18 , Apr 5, 2018 |  BC Extra  |  Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

SciFluor preclinical data

In rodents, SF0034 was “a more potent and less toxic” anticonvulsant than Trobalt retigabine. Additionally, SF0034 prevented the development of tinnitus in mice. Data were published in The Journal of Neuroscience. SF0034 is a potassium...
01:25 , Apr 23, 2015 |  BC Extra  |  Financial News

SciFluor raises $30M in series A

Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an untranched series A round led by new investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated...
07:00 , Sep 4, 2014 |  BC Innovations  |  Strategy

Meeting of the minds

Since its inception in 2006, Allied Minds plc has primarily invested in and incubated early stage research from U.S. academic institutions and federal labs, with a focus on medical devices and healthcare information technology. Now...
07:00 , Jun 27, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Tinnitus Potassium channel Kv7.2 (KCNQ2); KCNQ3 Mouse and cell culture studies suggest improving the activity of KCNQ2 and KCNQ3 could help...